Alpha 2.0
Login Register
» Articles » PMID: 39114324

Obinutuzumab-Induced Inflammatory Bowel Disease-Like Pancolitis: A First Case Report

Overview
Journal GE Port J Gastroenterol
Specialty Gastroenterology
Date 2024 Aug 8
PMID 39114324
Authors
Raquel R Mendes
Pedro C Figueiredo
Isabel Andrade
Affiliations
Soon will be listed here.
Abstract

Introduction: Obinutuzumab is a type II anti-CD20 monoclonal antibody associated with a higher rate of toxicity when compared to rituximab. Gastrointestinal side-effects have been reported but data is still sparse.

Case Presentation: A 47-year-old female with medical history of stage IV follicular non-Hodgkin lymphoma under chemotherapy presented with chronic bloody diarrhea and iron deficiency anemia. Endoscopic and histologic features resembled inflammatory bowel disease (IBD), imposing a thorough differential diagnosis. The diagnosis of obinutuzumab-induced pancolitis was made and the drug was suspended with subsequent clinical improvement.

Conclusion: This is the first case report of obinutuzumab-induced pancolitis. The challenging differential diagnosis of IBD required a multidisciplinary approach with subsequent outcome and management implications.

References
1.
Feakins R, Torres J, Borralho-Nunes P, Burisch J, Curdia Goncalves T, de Ridder L . ECCO Topical Review on Clinicopathological Spectrum and Differential Diagnosis of Inflammatory Bowel Disease. J Crohns Colitis. 2021; 16(3):343-368. DOI: 10.1093/ecco-jcc/jjab141. View
2.
Amitai I, Gafter-Gvili A, Shargian-Alon L, Raanani P, Gurion R . Obinutuzumab-related adverse events: A systematic review and meta-analysis. Hematol Oncol. 2020; 39(2):215-221. DOI: 10.1002/hon.2828. View
3.
Reggiani Bonetti L, Leoncini G, Daperno M, Principi M, Baronchelli C, Manenti S . Histopathology of non-IBD colitis practical recommendations from pathologists of IG-IBD Group. Dig Liver Dis. 2021; 53(8):950-957. DOI: 10.1016/j.dld.2021.01.026. View
4.
Morschhauser F, Le Gouill S, Feugier P, Bailly S, Nicolas-Virelizier E, Bijou F . Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study. Lancet Haematol. 2019; 6(8):e429-e437. DOI: 10.1016/S2352-3026(19)30089-4. View
5.
Mallepally N, Abu-Sbeih H, Ahmed O, Chen E, Shafi M, Neelapu S . Clinical Features of Rituximab-associated Gastrointestinal Toxicities. Am J Clin Oncol. 2019; 42(6):539-545. DOI: 10.1097/COC.0000000000000553. View